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Human immunodeficiency virus (HIV) viremia was evaluated in 73 patients with long-standing
infection to investigate its relationship with clinical or biologic parameters and to assess its use as
a predictor of clinical progression and death. After adjustment for other parameters, baseline HIV
RNA level was significantly associated with baseline clinical stage and CD4 cell count. During
follow-up (mean, 14.6 months), 16 patients died; 34 others had clinical progression of disease. In
multivariate analysis, mortality was better predicted by baseline CD4 cell count (relative hazard
[RH] for loo-cell decrease, 3.5; 95% confidenceinterval [CI], 1.5-8.2; P = .003) than by HIV RNA
(P = .28) or clinical stage. HIV RNA level was the best predictor of clinical progression (RH for 1
log increase, 2.8; 95% CI, 1.6-4.9; P < .001). Monitoring of HIV RNA level may help to identify
patients who might benefit from antiretroviral or prophylactic therapy.
Human immunodeficiency virus (HIV) disease progression
varies considerably among individuals, and treatment of HIV-
infected patients is guided by clinical and laboratory indicators
of disease activity. For instance, CD4 cell count is used to
guide therapeutic decisions [I, 2] and to define HIV infection
stage, including the onset of AIDS. A number of other clinical
and laboratory markers have been used to estimate prognosis
of HIV-infected patients [3,4], but all have limitations in sensi-
tivity, specificity, or predictive value.
Recent studies on the turnover of viremia and of CD4 cell
counts have underscored interindividual differences that do not
simply reflect HIV disease stages [5, 6]. In addition, increases
in CD4 cells after antiviral treatment do not always reflect
clinical benefit [7].
HIV viremia levels presumably reflect HIV load more di-
rectly than do CD4 cell counts and may provide useful prognos-
tic information. Cross-sectional studies have shown correla-
tions between viremia and stage of HIV disease or
seroimmunologic parameters, such as CD4 cell counts and neo-
pterin and ,Bz-microglobulin levels [8-10]. However, more
studies are needed to explore the potential predictive value of
viremia for clinical progression or death. Thus, we prospec-
tively assessed the use of HIV RNA level to predict clinical
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progression of HIV disease and death in a group of patients
infected with HIV for 7-II years.
Methods
Study design. This prospective study evaluated the prognostic
significance of HIV RNA level with regard to clinical progression
and death. A cross-sectional analysis was done to identify variables
associated with HIV RNA levels at baseline, because such vari-
ables could confound longitudinal associations between HIV RNA
levels and disease progression.
Patient enrollment and follow-up. Patients followed in the Ge-
neva AIDS Center and known to have contracted HIV before 1
January 1986 were eligible for this study. All were participants in
the Swiss HIV Cohort Study, which includes an estimated 70%
of Swiss AIDS patients and one-third to one-half of all HIV-
infected persons in Switzerland [11]. Patients were enrolled be-
tween November 1992 and July 1993 at a regular follow-up visit.
Of 114 potentially eligible patients, 74 agreed to participate and
completed the baseline assessment. One patient was later lost to
follow-up; the other 73 are included in this report. Follow-up was
terminated 30 September 1994.
Outcome variables. The two outcome variables were clinical
progression of HIV infection (minor opportunistic infections,
AIDS-defining events, or HIV-related death [12]) and death of
any cause. Dates of events, exact diagnosis of new opportunistic
infections, and cause of death was obtained from the patient's
attending physician.
Main predictor variable. The principal predictor variable was
the number of HIV RNA copies measured at baseline by quantita-
tive polymerase chain reaction. HIV RNA level was quantitated
in relation to an external standard [13]. In brief, total RNA was
purified from 50 J1.L of serum using the guanidium thiocyanate-
phenol-chloroform method. Total RNA was reverse transcribed,
and a 122-bp sequence (HIVHXB2: 4142-4264) of a conserved
region of the pol gene was amplified. HIV RNA levels were ex-
pressed as the logarithm of RNA copies per milliliter of serum.
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Potential confounders. Variables evaluated as confounding
factors included age, clinical stage of HIV disease, CD4 and CD8
cell counts, CD4:CD8 ratios, p24 antigenemia, .8rmicroglobuli-
nemia, and antiviral and prophylactic treatments at baseline (no
data were available for changes of treatment over time).
Cross-sectionalanalysis. Potential confounders were first as-
sessed for independent association with log (HIV RNA), and only
those that fulfilled this condition were retained for further evalua-
tion. These associations were explored using scatter plots for con-
tinuous variables and box plots for categorical variables. Linear
regression analysis of variance models was selected on the basis
of the exploratory analysis. A multivariate regression analysis
identified variables associated independently with HIV RNA.
Prospective analysis. HIV RNA values (in log copies per
milliliter) were divided into tertiles. In univariate analysis,
incidence rates of disease progression and mortality rates
(events per person-years of follow-up) were computed for each
tertile. Tertiles of HIV RNA were compared using Kaplan-
Meier analysis and log rank tests for linear trend [14]. HIV
RNA level was also modeled as a continuous variable in pro-
portional hazards models (hazard ratios were expressed for an
increase of 1 unit in log HIV RNA). Proportional hazards mod-
els were used for potential confounders identified in the cross-
sectional analysis. P < .05 was considered statistically sig-
nificant. Data were analyzed by statistical software (SPSS for
Windows; SPSS, Chicago).
Results
Baseline characteristics. Of the 73 participants, 54 (74%)
were men. Average age was 35 years (range, 27-52). Main
risk factors for HIV infection were intravenous drug use, 48
(66%); homosexual contact, 15 (21%); and other or unknown,
10 (13%). At the baseline visit, subjects had been HIV-posi-
tive an average of 9 years (range, 7-11); 42 patients (58%)
had received antiretroviral treatment; and 37 (51%) received
Pneumocystis carinii pneumonia prophylaxis. Twenty-two pa-
tients (30%) were CDC stage A, 31 (42%) were stage B, and
20 (27%) were stage C [13]. The mean (:±:SD)CD4 cell count
was 277 :±: 249/mm3. Twelve patients (16%) were category
I (~500/mm3), 27 (37%) were category 2 (200-499/mm3),
and 34 (47%) were category 3 (0-199/mm3). Overall, 37
patients (51%) had AIDS at baseline [13]. Mean (:±:SD)HIV
RNA was 5.28 :±: 0.90 log copies/mL. Tertiles were 2.49-
4.91 (lowest), 4.94-5.74 (middle), and 5.75-6.97 log copies/
mL (highest).
Relation ofHIV RNA levels to baseline parameters. Base-
line HIV RNA levels were similar in men and women (5.25
:±: 0.85 vs. 5.36 :±: 0.98 log copies/mL; P = .24) and in intrave-
nous drug users and male homosexuals (5.23 :±: 0.89 vs. 5.50
:±: 0.94 log copies/mL; P = .32). No association was observed
between HIV RNA level and age (Pearson's r = .07, P = .58).
HIV RNA level was inversely correlated with CD4 cell count
in patients with < 500 CD4 cells/mrrr', but there was no clear
association between HIV RNA level and CD4 cell count if
the latter exceeded 500/mm3 (figure 1). HIV RNA level was
inversely correlated with CD8 cell count and was positively
associated with levels of plasma .Brmicroglobulin and p24
antigen (table 1). Association with CD4:CD8 cell ratios ap-
7 ......,----------------------------,
Figure 1. Scatter plot with
Lowe's regression of log HIV RNA
level by CD4 cell counts of 73 pa-
tients with long-standing HIV infec-
tion (dashed line indicates > 500
CD4 cells/ram').
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Table 1. Univariate associations between HIV RNA level and pa-
rameters of disease progression in 73 patients with long-standing HIV
infection.
Variable Slope In log HIV RNNmL per P
CD4 cell counts
,,;;500 -0.25 100 CD4 cells/rnrrr' <.001
>500 0.04 .73
CD8 cell count -0.72 1000 CD8 cells/mrrr' <.001
CD4:CD8 cell ratios
,,;;0.4 -0.24 0.1 ratio units .003
>0.4 0.01 .88
.Brmicroglobulin 0.27 100 mg/L .004
p24 antigen 0.10 10 ng/L .002
peared to be strongly negative for the lowest values «0.4),
but no meaningful association was seen for higher values. HIV
RNA level varied considerably within each clinical stage of
HIV infection. Differences in mean values were statistically
significant between stages A and B (4.60 ::±:: 0.92 vs. 5.52 ::±::
0.75 log copies/mL, P < .001) and stages A and C (4.60 ::±::
0.92 vs. 5.65 ::±:: 0.70 log copies/mL, P < .001) but not between
stages Band C (P = .56).
In multivariate models, HIV RNA level remained indepen-
dently associated only with clinical stage (P = .005) and CD4
cell count (P = .05), while CD8 cell counts, CD4:CD8 cell
ratios, and .Brmicroglobulin and p24 antigen levels were no
longer significantly associated with HIV RNA levels.
Mortality. Sixteen patients died during follow-up (mean,
444 days; range, 11-705). Fourteen deaths were HIV related,
and 2 were suicides. The overall mortality rate was 0.18 per
person-year. Mortality rates were 0.07, 0.16, and 0.32 by in-
creasing HIV RNA tertile. The Kaplan-Meier analysis showed
that survival was similar in patient groups defined by HIV
RNA tertiles for the first 6-9 months of follow-up. These
groups only diverged in survival later (figure 2A; log rank test
for linear trend, P = .02). Results were similar when the 2
suicides were treated as nonevents (i.e., censored; data not
shown).
In univariate proportional hazards models, clinical stage and
CD4 cell count were better predictors of death than was HIV
RNA level (table 2). When HIV RNA, CD4 cell counts, and
clinical stages were included as covariates in the same model,
CD4 cell counts remained a strong, statistically significant pre-
dictor of death, while the predictive values of HIV RNA level
and clinical stages were no longer statistically significant. This
result was observed both when HIV RNA level was categorized
into tertiles and when it was analyzed as a continuous variable.
In the latter analysis, the relative hazard of death was 2.8 (95%
confidence interval [CI], 1.4-5.6; P = .003) per 1 log increase
in univariate models and 1.5 (95% CI, 0.7-3.0; P = .28) after
adjustment for CD4 cell counts and clinical stages.
Clinical progression. During follow-up, 34 patients (47%)
had 28 new opportunistic infections over an average of 345
days at risk: esophageal candidiasis and Candida stomatitis (4
each); bacterial pneumonia, weight loss, generalized herpes
zoster, or other opportunistic infections (3 each); cryptospori-
diosis (2); and cytomegalovirus retinitis, oral leukoplakia, cere-
bral toxoplasmosis, P. carinii pneumonia, chronic diarrhea, and
atypical mycobacterial infection (1 each). Eight patients died
without developing a new opportunistic infection: 6 of HIV-
related diseases that were considered to be clinical progression
and 2 by suicide. The latter 2 were censored at the time of
death for analysis of disease progression. The overall incidence
rate of clinical progression was 0.49 events per person-year.
Incidence rates were 0.20, 0.36, and 1.22 events per person-
year by increasing HIV RNA tertile. Kaplan-Meier analysis
showed striking differences in the rates of progression between
patients in the highest HIV RNA terti le and the 2 other groups
(figure 2B; log rank test for linear trend, P < .001).
In contrast to the analysis of mortality results, Cox modeling
of the hazard of clinical progression identified baseline HIV
RNA level as the best predictor (table 3). HIV RNA level was
a strong predictor of clinical progression in all models, whereas
CD4 cell counts were statistically significant predictors only
in univariate analysis and became nonsignificant in models
adjusted for HIV RNA level and clinical stage. The clinical
stage at baseline did not predict well the incidence of clinical
progression. The risk of clinical progression was increased
almost 2-fold in the middle HIV RNA tertile relative to the
lowest terti le and ~6-fold in the highest tertile. In multivariate
analysis, treatment at baseline (antiviral and prophylaxis of
opportunistic infections) did not confound the association be-
tween viremia and clinical progression. When HIV RNA level
was analyzed as a continuous variable, the relative hazard of
clinical progression was 2.8 (95% CI, 1.7-4.5; P < .001) per
1 log increase in univariate analysis and 2.8 (95% CI, 1.6-
4.9; P < .001) in multivariate analysis. Repetition of the analy-
sis after exclusion of minor opportunistic infections provided
similar results, although with a larger CI due to the smaller
number of events (data not shown).
Discussion
Results of this prospective study suggest that HIV RNA
level is a strong independent predictor of clinical progression
in patients with long-standing HIV infection. In contrast, HIV
RNA levels did not predict death independently: Death was
best predicted by CD4 cell count. These results indicate that
assessment of HIV RNA level might be a useful tool in the
clinical management of HIV-infected patients.
Patients with HIV RNA levels >5.75 log copies/mL had
~ 1.22 opportunistic infections per person-year. Such a risk
level may justify close clinical surveillance, prophylaxis against
opportunistic infections, and aggressive antiviral treatment di-
rected against HIV, regardless of CD4 cell count. In this re-
spect, among the 24 patients with HIV RNA level ??-5.75 log
copies/mL, 7 had > 200 CD4 cells/mrrr'. Of these 7, 5 were
asymptomatic and would not require primary prophylaxis
against opportunistic infections by current guidelines. Only
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Figure 2. Kaplan-Meier curves
show survival (A) and survival free
of clinical progression (D) by base-
line HIV RNA tertile (lowest, solid
line, 2.49-4.91 log copies/mL; mid-
dle, long dashes, 4.94-5.74; highest,
short dashes, 5.75-6.97).
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1 received prophylaxis against P. carinii pneumonia. During
follow-up, 4 of the 5 patients developed new opportunistic
infections. The clinical benefit of various therapeutic and pro-
phylactic interventions in patients with high circulating levels
of HIV RNA should be evaluated in randomized trials.
HIV RNA level was determined using an in-house assay;
lower levels might be measured using commercial assays. In
this context, the HIV RNA levels reported here should not be
considered absolute values but rather as supporting the concept
that patients with high HIV RNA values have an increased risk
of developing opportunistic infections.
This study included a selected patient population infected
before 1986 and alive in 1993. Ofpersons infected before 1986,
49% died before this study began (data not shown). Patients
in our study represented a full spectrum of HIV disease (by
CDC classification) and did not differ markedly from the pa-
tient population in the Swiss HIV Cohort Study [11]. This
suggests that the present results might be extended to the gen-
eral HIV-infected population. These data are also in agreement
with two recent studies on seroconverters followed several
years, which showed that viremia level predicted clinical out-
come [15, 16].
The different predictive values of CD4 cell counts and HIV
RNA levels may be related to methodologic issues or to differ-
ent pathogenic mechanisms. The inability of HIV RNA levels
to predict mortality after CD4 cell counts have been taken into
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Table 2. Relative hazards of death by HIV RNA level, clinical stage of HIV disease, and CD4 cell
count at baseline in 73 patients infected with HIV for 7-11 years.
Univariate analysis Multivariate analysis
RH (95% CI) p* RH (95% CI) P
HIY RNA tertile .10 .81
Lowest 1.0 1.0
Middle 2.3 (0.4-11.6) 1.7 (0.3-8.8)
Highest 4.7 (1.0-21.9) 1.6 (0.3-8.0)
Clinical stage .001 .67
A 1.0 1.0
B 3.8 (0.4-32.5) 1.0 (0.1-8.6)
C 13.7 (1.8-107.4) 1.5 (0.2-13.9)
CD4 cell count (continuous)/
decrease of 100 cells/mrrr' 4.0 (1.8-9.0) <.001 3.5 (1.5-8.2) .003
NOTE. RH, relative hazard; CI, confidence interval.
* Based on Wald statistic for all levels of variable.
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account may simply be due to overadjustment. If an increase
in HIV RNA level is the main cause of CD4 depletion [5, 6],
which in turn leads to death, then adjustment for the intervening
variable (CD4 cell count) would erase the association between
the primary cause (HIV RNA) and the outcome of interest
(death). On the other hand, active viral replication might in-
crease the occurrence ofopportunistic infections through mech-
anisms that do not necessarily involve CD4 cell depletion. One
such mechanism might be activation of latent or chronic viral
infections. Activation of HIV replication occurs both in vitro
and in vivo. Infection by herpes group viruses and by the
hepatitis B virus activates HIV replication [17-21]. The reverse
might also be true; that is, increased HIV replication may acti-
vate other latent infections. Another mechanism might be a
virus-induced destruction of monocytes and macrophages that
might facilitate the spread of superinfections by intracellular
parasites [22, 23]. Finally, the small study sample (only 14
deaths attributed to HIV infection) might have precluded the
finding of a direct relationship between RNA level and mortal-
ity, which might be found in studies with larger patient popula-
.tions.
In conclusion, our data highlight the value ofHIV RNA level
as an independent predictor of disease progression. Routine
measurement of circulating levels of HIV RNA may identify
patients at high risk of opportunistic infections who do not
currently qualify for antiretroviral therapy or for preventive
treatment of opportunistic infections on the basis of their CD4
cell counts. These patients should be considered for early thera-
peutic intervention.
Swiss HIV Cohort Study Group Members
Study group members are M.Battegay, P. Burgisser, R. Doody,
M. Egger, P. Erb, W. Fierz, M. Flepp, P. Francioli, P. Grob, U.
Table 3. Relative hazards of clinical progression by HIV RNA level, clinical stage of HIV disease,
and CD4 cell count at baseline in 73 patients infectedwith HIV for 7-11 years.
Univariate analysis Multivariate analysis
RH (95%) CI) p* RH (95% CI) p*
HIY RNA tertile <.001 <.001
Lowest 1.0 1.0
Middle 1.8 (0.6-5.4) 1.8 (0.6-5.4)
Highest 6.4 (2.3-17.3) 6.1 (2.1-17.9)
Clinical stage .09 .36
A 1.0 1.0
B 1.2 (0.5-3.1) 0.5 (0.2-1.5)
C 2.4 (1.0-6.0) 0.9 (0.3-2.4)
CD4 cell counts (continuous)/
decrease of 100 cells/mrrr' 1.3 (1.1-1.6) .005 1.2 (1.0-1.5) .09
NOTE. RH, relative hazard; CI, confidence interval.
* Based on Wald statistic for all levels of variable.
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